Showing 6251-6260 of 8826 results for "".
- Treatment Options to Consider for Pregnant Women Living with Eczema and Psoriasishttps://practicaldermatology.com/news/treatment-options-to-consider-for-pregnant-women-living-with-eczema-and-psoriasis/2461639/Psoriasis and eczema affect men and women differently, with women needing to take extra precautions when considering treatments if they’re planning for pregnancy, according to a news release from the American Academy of Dermatology. At the recent American Academy of Dermatology&rs
- New North Carolina Courage Jerseys to Feature Merz Aesthetics Sponsorshiphttps://practicaldermatology.com/news/new-north-carolina-courage-jerseys-to-feature-merz-aesthetics-sponsorship-1/2461632/Merz Aesthetics North America has launched its front-of-jersey sponsorship deal with the
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoria
- Cutera Updates truBody Brandhttps://practicaldermatology.com/news/cutera-updates-trubody-brand/2461605/Cutera has launched an updated truBody brand that pairs two technologies designed to create a customized, convenient, and complete approach to fat reduction and muscle toning with 15-minute treatment options, according to a company news release. The new truBody brand elevates both pract
- BTL Takes a Stand Against Illegal and Counterfeit Aesthetic Deviceshttps://practicaldermatology.com/news/btl-takes-a-stand-against-illegal-and-counterfeit-aesthetic-devices/2461593/BTL is making inroads in its efforts to safeguard medical providers and consumers from counterfeit devices in the United States through legal action and the seizure of illegally imported devices at the border. BTL has filed court documents stating that defendants use and sell knock
- Fewer Cases of Melanoma, Cancers in Extracutaneous Sites Seen in Patients with Atopyhttps://practicaldermatology.com/news/fewer-cases-of-melanoma-cancers-in-extracutaneous-sites-seen-in-patients-with-atopy/2461591/Fewer cases of melanoma are observed in people with a history of atopic diseases, such as allergic asthma or rhinitis, than in nonatopic people, according to a new study in Melanoma Research. Specifically, the risk of melanoma in people with atopy was up to 50% lower than
- U.S. FDA: Renuvion Cleared to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissuehttps://practicaldermatology.com/news/us-fda-renuvion-cleared-to-coagulate-and-contract-soft-tissues-including-subcutaneous-tissue/2461590/The U.S. Food and Drug Administration (FDA) has cleared the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. (Soft tissue includes subcutaneous tissue.) “We are pleas
- Dyskerin May Signal When SCC Is On The Movehttps://practicaldermatology.com/news/dyskerin-may-signal-when-scc-is-on-the-move/2461585/The protein dyskerin may provide important clues as to how cutaneous squamous cell carcinoma tumors prepare themselves to migrate to the lymph nodes to metastasize other organs, a new study suggests. These cells stop consuming glucose so that they can survive by using LDL chol